Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies

Savarirayan, R; De Bergua, JM; Arundel, P; McDevitt, H; Cormier-Daire, V; Saraff, V; Skae, M; Delgado, B; Leiva-Gea, A; Santos-Simarro, F; Salles, JP; Nicolino, M; Rossi, M; Kannu, P; Bober, MB; Phillips, J; Saal, H; Harmatz, P; Burren, C; Gotway, G; Cho, T; Muslimova, E; Weng, R; Rogoff, D; Hoover-Fong, J; Irving, M – 2022